LAUSR

REFERENCES 1. Schnell BR, Seipel K, Bacher U, et al. Rebound thrombocytosis after induction chemotherapy is a strong biomarker for favorable outcome in AML patients. HemaSphere. 2019;3(2):e180. 2. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. 3. Daly ME. Determinants of platelet count in humans. Haematologica. 2011;96(1):10-13. 4. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383 (7):617-629. 5. Pollyea DA, Dinardo CD, Arellano ML, et al. Results of Venetoclax and Azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH 1/2 mutations. Blood. 2020;136 (Supplement 1):5-7. 6. Rauch PJ, Ellegast JM, Widmer CC, et al. MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. Blood. 2016;128(18):2253-2257.